Neovacs: presents results from vaccine candidates

(CercleFinance.com) - Neovacs, a pre-clinical biopharmaceutical company developing novel therapies for inflammatory and autoimmune diseases, announces that work on its IL-4/IL-13 and IgE therapeutic vaccines has been presented at two international meetings.


The presentations were made at the EMBRN conference in Toulouse and the EAACI Congress in Valencia, Spain.

The results presented at these two conferences demonstrate that the IgE vaccine induces long-term protection against allergy in humanized mouse models.

Indeed, our results showed the production of antibodies neutralizing the pathogenic activity of IgE for up to a year after administration of the IgE vaccine in humanized mice, with no significant adverse effects. This vaccination reduces circulating IgE antibodies and provides long-lasting protection against anaphylactic shock, the most severe clinical manifestation of allergy.

Copyright (c) 2024 CercleFinance.com. All rights reserved.